Abstract:Importance: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. Patients typically respond to initial chemotherapy but quickly experience relapse, resulting in a poor long-term outcome. Therapeutic innovations that substantially improve survival have historically been limited, and reliable, predictive biomarkers are lacking. Observations: This review examines the biologic characteristics of SCLC, the current treatment landscape, and ongoing efforts to identify novel therapeutic targets. Ongoing research has advanced the understanding of molecular categories and the immunologic microenvironment of SCLC, which in turn has helped improve disease classification and staging. Recently, immunotherapy-based regimens have become available for the management of SCLC, with 2 programmed cell death 1 ligand 1 inhibitors approved in combination with chemotherapy for first-line treatment of extensive-stage disease. For second-line treatment, a novel alkylating agent, lurbinectedin, which inhibits oncogenic transcription, has been approved for use in patients with metastatic SCLC. Furthermore, a wide variety of therapies and innovative combination regimens are being continuously evaluated. Potential therapeutic strategies, including aurora kinase A inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors, ataxia telangiectasia and Rad3-related inhibitors, cyclin-dependent kinase 7 inhibitors, delta-like protein 3 agents, antiganglioside agents, CD47 inhibitors, and lysine-specific histone demethylase 1a inhibitors, are also being examined. Conclusions and relevance: Therapeutic optimization of SCLC remains a challenge, but recent trial results and drug approvals are encouraging. Advances in research have revealed critical information regarding biologic characteristics of the disease, which may lead to the identification of vulnerabilities and the development of new therapies. Further research focused on identifying biomarkers and evaluating innovative therapies will be paramount to improving treatment outcomes for patients with SCLC.

Research Progress of Anti-Angiogenic Drugs in First-Line Treatment of Small Cell Lung Cancer

Research Progression on Anti-Angiogenesis Therapy for Small Cell Lung Cancer

Advances in antiangiogenic treatment of small-cell lung cancer

Current Status and Progress of the Treatment of Limited-Disease Small Cell Lung Cancer

Treatment of Small Cell Lung Cancer: Recent Advances

The research advances of drug therapy of small cell lung cancer

Research progress in the treatment of small cell lung cancer

Current Small Cell Lung Cancer Treatment In China

Update of Research on Drug Resistance in Small Cell Lung Cancer Chemotherapy

Research on Chemoresistance of Small Cell Lung Cancer

What’s New in the Treatment of Advanced Small-Cell Lung Cancer

New insights into small‐cell lung cancer development and therapy

Angiogenesis Inhibitors in Small Cell Lung Cancer

Current Status and Progress of CAR-T Cell Therapy in the Treatment of Small Cell Lung Cancer

Progress in Targeted Therapy for Small Cell Lung Cancer

Treatment strategies and progress of recurrent small cell lung cancer

Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy

Molecular biology progress of small cell lung cancer

Newly developed anti-angiogenic therapy in non-small cell lung cancer

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review

[Recent Advances and Future Strategies for Small Cell Lung Cancer].